Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 6/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257854 | 1.00 | TK2 (0.31) | TK2TYMPTK1 | |
| SCHEMBL6830095 | 0.83 | TK2 (0.35) | TK2TK1 | |
| SCHEMBL1097588 | 0.83 | TYMP (0.32) | TK2TYMPTK1 | |
| SCHEMBL6829890 | 0.82 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL1096963 | 0.81 | TK2 (0.32) | TK2TYMPTK1 | |
| SCHEMBL1096934 | 0.79 | TYMP (0.39) | TK2TYMPTK1 | |
| SCHEMBL6863542 | 0.79 | TYMP (0.39) | TK2TYMPTK1 | |
| SCHEMBL22984007 | 0.78 | RNASE1 (0.40) | TK2TYMPTK1 | |
| SCHEMBL13901245 | 0.78 | RNASE1 (0.40) | TK2TYMPTK1 | |
| SCHEMBL13930549 | 0.78 | RNASE1 (0.40) | TK2TYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8080644-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-12-20 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2253639-A1 | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2010-11-24 | — | — | EP | disclosed |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-11-04 | — | — | US | disclosed |
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| US-7572582-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2009-08-11 | — | — | US | disclosed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | TK2 55/4885TYMP 19/4885TK1 26/4885 |
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | TK2 55/4885TYMP 19/4885TK1 26/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | TK2 126/4885TYMP 61/4885TK1 53/4885 |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | TK2 55/4885TYMP 19/4885TK1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.